Clinical Trials · NCT06269120
SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
- Phase
- N/A
- Recruitment status
- Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 470
- Start date
- Sep 2024
- Locations
- 1 site, Hungary
- Primary endpoint
- Glycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5%